Akebia Therapeutics, Inc.

AKBA· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$1.31-0.76%

2026-08-03

Financials

Valuation Metrics

Akebia Therapeutics, Inc.'s Market Cap is $351M. At end of 2025 it was $427M. Ranked #2925 of 3,112 in US market (top 94%), #1303 of 1,445 on NASDAQ (top 90%), #237 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 88%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$351M	US#2,925/3,112 Sec#237/269
Revenue	$232M	US#2,642/3,112 Sec#106/269
Net Income	$-21M	US—/3,112 Sec—/269
Total Assets	$363M	US#2,852/3,112 Sec#192/269
Net Assets	$27M	US#2,970/3,112 Sec#251/269
Value
P/B	12.84x	US#2,688/3,112 Sec#214/269
P/S	1.51x	US#987/3,112 Sec#20/269
FCF Yield	17.06%	US#185/3,112 Sec#7/269
Profitability
ROE	-74.93%	US#2,819/3,112 Sec#211/269
ROA	-5.66%	US#2,549/3,112 Sec#94/269
Op. Margin	2.28%	US#2,292/3,112 Sec#80/269
Revenue Growth	-6.61%	US#2,567/3,112 Sec#140/269
Earnings Growth	-248.13%	US#2,255/3,112 Sec#83/269
Financial Health
Debt Ratio	1224.27%	US#2,828/3,112 Sec#250/269
Total Debt	$12M	US#2,761/3,112 Sec#192/269
FCF	$60M	US#1,868/3,112 Sec#67/269
Cash	$163M	US#1,884/3,112 Sec#136/269
Current Ratio	1.40x	US#1,772/3,112 Sec#249/269
Performance
1Y Return	-64.78%	US#3,068/3,112 Sec#260/269
1M Return	5.65%	US#893/3,112 Sec#35/269
From 52W High	-65.44%	US#2,982/3,112 Sec#247/269
1Y MDD	-78.23%	US#3,031/3,112 Sec#257/269
Trading
Volume	2,080,866 shares	US#865/3,112 Sec#77/269
Trading Value	$3M	US#2,846/3,112 Sec#238/269
Per Share
EPS	$-0.02	US—/3,112 Sec—/269
BPS	$0.12	US#2,713/3,112 Sec#230/269